Expasy logo

UniProtKB/Swiss-Prot variant pages

UniProtKB/Swiss-Prot P35557: Variant p.Ser441Trp

Hexokinase-4
Gene: GCK
Feedback?
Variant information Variant position: help 441 The position of the amino-acid change on the UniProtKB canonical protein sequence.
Type of variant: help LP/P [Disclaimer] The variants are classified into three categories: LP/P, LB/B and US.
  • LP/P: likely pathogenic or pathogenic.
  • LB/B: likely benign or benign.
  • US: uncertain significance
Residue change: help From Serine (S) to Tryptophan (W) at position 441 (S441W, p.Ser441Trp). Indicates the amino acid change of the variant. The one-letter and three-letter codes for amino acids used in UniProtKB/Swiss-Prot are those adopted by the commission on Biochemical Nomenclature of the IUPAC-IUB.
Physico-chemical properties: help Change from small size and polar (S) to large size and aromatic (W) The physico-chemical property of the reference and variant residues and the change implicated.
BLOSUM score: help -3 The score within a Blosum matrix for the corresponding wild-type to variant amino acid change. The log-odds score measures the logarithm for the ratio of the likelihood of two amino acids appearing by chance. The Blosum62 substitution matrix is used. This substitution matrix contains scores for all possible exchanges of one amino acid with another:
  • Lowest score: -4 (low probability of substitution).
  • Highest score: 11 (high probability of substitution).
More information can be found on the following page
Variant description: help In MODY2; decreased affinity for glucose. Any additional useful information about the variant.


Sequence information Variant position: help 441 The position of the amino-acid change on the UniProtKB canonical protein sequence.
Protein sequence length: help 465 The length of the canonical sequence.
Location on the sequence: help ERFHASVRRLTPSCEITFIE S EEGSGRGAALVSAVACKKAC The residue change on the sequence. Unless the variant is located at the beginning or at the end of the protein sequence, both residues upstream (20) and downstream (20) of the variant will be shown.
Residue conservation: help The multiple alignment of the region surrounding the variant against various orthologous sequences. 
Human                         ERFHASVRRLTPSCEITFIESEEGSGRGAALVSAVACKKAC

Mouse                         ERFHASVRRLTPNCEITFIESEEGSGRGAALVSAVACKKAC

Rat                           ERFHASVRRLTPNCEITFIESEEGSGRGAALVSAVACKKAC
Sequence annotation in neighborhood: help The regions or sites of interest surrounding the variant. In general the features listed are posttranslational modifications, binding sites, enzyme active sites, local secondary structure or other characteristics reported in the cited references. The "Sequence annotation in neighborhood" lines have a fixed format:
  • Type: the type of sequence feature.
  • Positions: endpoints of the sequence feature.
  • Description: contains additional information about the feature.
TypePositionsDescription
Chain 1 – 465 Hexokinase-4
Domain 10 – 454 Hexokinase
Region 204 – 443 Hexokinase large subdomain
Mutagenesis 453 – 453 S -> A. Increased glucokinase activity based on measure of catalytic efficiency. Increased affinity for glucose.



Literature citations
Identification of novel and recurrent glucokinase mutations in Belgian and Luxembourg maturity onset diabetes of the young patients.
Vits L.; Beckers D.; Craen M.; de Beaufort C.; Vanfleteren E.; Dahan K.; Nollet A.; Vanhaverbeke G.; Imschoot S.V.; Bourguignon J.P.; Beauloye V.; Storm K.; Massa G.; Giri M.; Nobels F.; De Schepper J.; Rooman R.; Van den Bruel A.; Mathieu C.; Wuyts W.;
Clin. Genet. 70:355-359(2006)
Cited for: VARIANTS MODY2 TRP-36; TYR-129; LEU-152; VAL-188; TRP-191; ARG-202; SER-223; MET-226; HIS-231; PHE-315; THR-378; PHE-434; TRP-441 AND GLN-447; Mutations in GCK and HNF-1alpha explain the majority of cases with clinical diagnosis of MODY in Spain.
Estalella I.; Rica I.; Perez de Nanclares G.; Bilbao J.R.; Vazquez J.A.; San Pedro J.I.; Busturia M.A.; Castano L.;
Clin. Endocrinol. (Oxf.) 67:538-546(2007)
Cited for: VARIANTS MODY2 GLU-16; ASN-19; PRO-20; TRP-36; SER-43; SER-44; 61-TYR--GLN-465 DEL; SER-61; LYS-70; ARG-72; PRO-77; GLU-78; ASP-80; ILE-82; HIS-108; PRO-116; LEU-182; 186-ARG--GLN-465 DEL; TYR-187; TRP-191; LEU-200; THR-202; MET-206; MET-209; SER-223; ARG-224; SER-227; MET-228; ARG-233; 234-TYR--GLN-465 DEL; GLY-252; ALA-255; LYS-256; ARG-261; LYS-265; LYS-298; TRP-308; HIS-377; VAL-379; LEU-383; 399-GLU--GLN-465 DEL; PHE-411; PRO-416; GLU-420 AND TRP-441; Opposite clinical phenotypes of glucokinase disease: Description of a novel activating mutation and contiguous inactivating mutations in human glucokinase (GCK) gene.
Barbetti F.; Cobo-Vuilleumier N.; Dionisi-Vici C.; Toni S.; Ciampalini P.; Massa O.; Rodriguez-Bada P.; Colombo C.; Lenzi L.; Garcia-Gimeno M.A.; Bermudez-Silva F.J.; Rodriguez de Fonseca F.; Banin P.; Aledo J.C.; Baixeras E.; Sanz P.; Cuesta-Munoz A.L.;
Mol. Endocrinol. 23:1983-1989(2009)
Cited for: VARIANT MODY2 TRP-441; CHARACTERIZATION OF VARIANT MODY2 TRP-441; VARIANT HHF3 LYS-442; CHARACTERIZATION OF VARIANT HHF3 LYS-442;
Disclaimer: Any medical or genetic information present in this entry is provided for research, educational and informational purposes only. They are not in any way intended to be used as a substitute for professional medical advice, diagnostic, treatment or care.